QuickView for Mitogen-activated protein (MAP) kinase, ERK1/2 (biogroup)

1. L1000 CMAP Breast cancer MCF7 cells with gene overexpression perturbations
2. PBMCs from Schnitzler's syndrome patients treated with anakinra or canakinumab
3. L1000 CMAP - Hepatocellular carcinoma Hep G2 cells with shRNA-mediated gene knockdown (1 of 2)
4. Venous blood from typhoid, paratyphoid, and malaria treatment and recovery timecourse
5. L1000 CMAP Prostate cancer PC3 cells with gene overexpression perturbations (2 of 2)

There were no matches for Mitogen-activated protein (MAP) kinase, ERK1/2

There were no clinical trials for Mitogen-activated protein (MAP) kinase, ERK1/2